Heart & blood pressure · Portland area, OR
Heart and blood pressure studies in Portland area, OR
29 recruiting studies have a site in the Portland area. This page includes nearby cities such as Beaverton, Hillsboro, Gresham, Tigard.
29 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics
- Location
- Portland, OR + 64 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Prevail Global Study
Medtronic Vascular
- Location
- Portland, OR + 53 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S
- Location
- Portland, OR + 58 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
Boston Scientific Corporation
- Location
- Portland, OR + 46 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
- Location
- Portland, OR + 40 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
Supira Medical
- Location
- Portland, OR + 24 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
AstraZeneca
- Location
- Portland, OR + 93 other US sites
- Eligibility basics
- Ages 18–130
- RecruitingPhase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Cytokinetics
- Location
- Portland, OR + 80 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
ELEVATE High-Risk PCI Pivotal Study
Magenta Medical Ltd.
- Location
- Clackamas, OR + 32 other US sites
- Eligibility basics
- Ages 18–88
- RecruitingPhase 2/Phase 3
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Kardigan, Inc.
- Location
- Portland, OR + 26 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Shockwave Medical, Inc.
- Location
- Portland, OR + 66 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
Edwards Lifesciences
- Location
- Clackamas, OR + 30 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Eli Lilly and Company
- Location
- Clackamas, OR + 120 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
CRISPR Therapeutics AG
- Location
- Portland, OR + 7 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Medtronic Cardiovascular
- Location
- Portland, OR + 68 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
BrioHealth Solutions, Inc.
- Location
- Portland, OR + 46 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 1/Phase 2
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.
- Location
- Portland, OR + 6 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
Cytokinetics
- Location
- Portland, OR + 23 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Portland, OR + 39 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
FORWARD CAD IDE Study
Shockwave Medical, Inc.
- Location
- Portland, OR + 27 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Endotronix, Inc.
- Location
- Portland, OR + 43 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Abbott Medical Devices
- Location
- Portland, OR + 56 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
- Location
- Portland, OR + 19 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
Cardiac Dimensions, Inc.
- Location
- Portland, OR + 50 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.